An IQ Consortium Perspective on Best Practices for Bioanalytical and Immunogenicity Assessment Aspects of CAR‐T and TCR‐T Cellular Therapies Development
Jochem Gokemeijer(Bristol-Myers Squibb (Germany)), Vibha Jawa(Bristol-Myers Squibb (Germany)), Swati Gupta(AbbVie (United States)), Weifeng Xu(Merck & Co., Inc., Rahway, NJ, USA (United States)), Sophie Tourdot(Pfizer (United States)), K. OGASAWARA(Bristol-Myers Squibb (United States)), Robert Dodge(Novartis (United States)), Tong‐Yuan Yang(Janssen (United States)), Joanna Grudzinska‐Goebel(Bayer (Germany)), Kate Herr(Johnson & Johnson (United States)), Venkata R. Vepachedu(Johnson & Johnson (United States)), Edit Tarcsa(Massachusetts Academy of Math and Science at WPI), Hardik Mody(Kaiser Permanente South San Francisco Medical Center), Nanda Balasubramanian(Bristol-Myers Squibb (United States)), Siddha Kasar(AVEO Oncology (United States)), Vijay Upreti(Amgen (United States))
Cited by 9
Related Papers
Immunogenicity assessment of AAV-based gene therapies: An IQ consortium industry white paper
|Molecular Therapy — Methods & Clinical Development|2022|113